Knight Therapeutics (TSE:GUD) Sets New 12-Month High - Here's Why

Key Points

• Shares hit a new 52-week high: Knight Therapeutics (TSE:GUD) traded as high as C$7.70 (last C$7.60) on Monday, up about 1.2% with roughly 47,408 shares changing hands.
• Mixed fundamentals: The company has a market cap of ~C$749.2M, a negative P/E of -152.8 and debt-to-equity of 10.15; it reported C$0.09 EPS and C$133.2M revenue for the quarter but a negative net margin (-1.19%).
• Business focus: Knight is a specialty and generic pharmaceutical company that develops, in-licenses, markets and distributes drugs, consumer health products and medical devices, and also finances other life-sciences companies to secure distribution rights.

Shares of Knight Therapeutics Inc. (TSE:GUD - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as C$7.70 and last traded at C$7.60, with a volume of 47408 shares traded. The stock had previously closed at C$7.55.

Knight Therapeutics Trading Up 1.2%

The company has a current ratio of 2.39, a quick ratio of 1.79 and a debt-to-equity ratio of 10.15. The firm has a market capitalization of C$749.15 million, a P/E ratio of -152.80, a P/E/G ratio of -1,013.50 and a beta of -0.29. The firm has a 50-day moving average of C$6.54 and a two-hundred day moving average of C$6.15.

Knight Therapeutics (TSE:GUD - Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The company reported C$0.09 earnings per share for the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%.The business had revenue of C$133.20 million during the quarter. On average, analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.